TY  - GEN
AU  - Pott,Christiane
AU  - Sehn,Laurie H
AU  - Belada,David
AU  - Gribben,John
AU  - Hoster,Eva
AU  - Kahl,Brad
AU  - Kehden,Britta
AU  - Nicolas-Virelizier,Emmanuelle
AU  - Spielewoy,Nathalie
AU  - Fingerle-Rowson,Guenter
AU  - Harbron,Chris
AU  - Mundt,Kirsten
AU  - Wassner-Fritsch,Elisabeth
AU  - Cheson,Bruce D
TI  - MRD response in relapsed/refractory FL after obinutuzumab plus bendamustine or bendamustine alone in the GADOLIN trial
SN  - 1476-5551
PY  - 2020///0804
KW  - Adult
KW  - Aged
KW  - Aged, 80 and over
KW  - Antibodies, Monoclonal, Humanized
KW  - administration & dosage
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - therapeutic use
KW  - Bendamustine Hydrochloride
KW  - Female
KW  - Humans
KW  - Lymphoma, Follicular
KW  - drug therapy
KW  - Lymphoma, Non-Hodgkin
KW  - Male
KW  - Middle Aged
KW  - Neoplasm, Residual
KW  - Progression-Free Survival
KW  - Rituximab
N1  - Publication Type: Journal Article; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1038/s41375-019-0559-9
ER  -